Modern day sensors have come a long way from their predecessors, which used
transistors made of bulky semi-conducting materials. Advent of micro fabrication
technology has led to miniaturization of biosensors. Indeed under stages of
development currently are nano-sized electronic components. However, biosensors
market is characterized by slower pace of commercialization, which is primarily
attributed to high cost, availability of effective alternative technologies,
and issues related to stability, sensitivity, and quality assurance. Biosensors
in medical applications remains a hugely untapped market, attracting several
new players, who in hopes of leveraging dormant market opportunities, are foraying
into the marketplace.
As stated by the recent report published by Global Industry Analysts Inc, United
States and Europe dominate the global market for medical biosensors, collectively
capturing 69.73% share estimated in 2008. The market in Asia-Pacific is projected
to reach US$794 million by the year 2012. In medical diagnostics, majority of
the biosensors (about 90%) are included in blood gas analyzers, electrolyte
analyzers, glucose meters, and metabolite analyzers.
Over half of the biosensors produced worldwide are employed in glucose meters.
With a diabetes epidemic underway, there exists strong growth opportunities
for diabetes management tools, such as glucose meters. Over the years, glucose-monitoring
meters have undergone a sea change, with recent entries featuring wireless and
sensor technologies and noninvasive glucose monitors. Sales in United States,
the largest market for Glucose biosensors is expected to reach US$1.28 billion
by 2012. In Europe, Germany, United Kingdom and France, together, collar 55.3%
of the biosensors market estimated in 2008. Bioluminescence-based biosensors
gained immense popularity as a screening procedure for testing water quality
in the key nations such as France, Germany, Spain and Sweden. Revenues in the
German Environmental Biosensors market are projected to climb at the fastest
rate to reach US$32.7 million by the year 2015.
The biosensors industry comprises of two types of participants including companies
developing biosensor-based devices and developers of biosensor technology. Key
players engaged in developing biosensor technology include AgaMatrix Inc., Cranfield
Biotechnology Center, LifeSensors Inc., M-Biotech, and Nova Biomedical. Leading
manufacturers of biosensor-based devices include - Abbott Point Of Care Inc.,
Affinity Sensors, Neosensors Limited, Siemens Healthcare Diagnostics Inc, Animas
Corporation, LifeScan Inc., Medtronic Diabetes, and Roche Diagnostics Ltd.
The report titled "Biosensors in Medical Diagnostics: A Global Strategic
Business Report" published by Global Industry Analysts, Inc., covers major
market dynamics, trends, issues, and competition pertaining to the market. The
report enumerates recent developments, mergers, acquisitions and other strategic
industry activities. The report analyzes the market across three major product
categories, namely Medical Biosensors (Glucose Biosensors and Other Medical
Biosensors), Environmental Biosensors, and Other Biosensors. The report reviews
various factors impeding the commercialization of biosensors. Apart from exploring
applications in medical diagnostics, the report offers a broader perspective
of biosensors by examining environmental, and industrial applications. Analysis
is presented for established and emerging markets including United States, Canada,
Japan, France, Germany, United Kingdom, Italy, Asia-Pacific, and Latin America.
For more details of this research report, please visit http://www.strategyr.com/Biosensors_in_Medical_Diagnostics_Market_Report.asp.